Discussion
A pivotal Phase 2/3 clinical trial comparing the experimental oral therapy CB03-154 with a placebo in people with amyotrophic lateral sclerosis (ALS) has completed enrollment in China, developer Zhimeng Biopharma announced. China’s Center for Drug Evaluation (CDE) cleared the trial to begin last year. It…